On Oct 30, 2025, INSM reported earnings of -1.75 USD per share (EPS) for Q3 25, missing the estimate of -1.36 USD, resulting in a -28.09% surprise. Revenue reached 142.34 million, compared to an expected 117.92 million, with a 20.71% difference. The market reacted with a +16.33% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 19 analysts forecast an EPS of -1.33 USD, with revenue projected to reach 174.83 million USD, implying an decrease of -24.00% EPS, and increase of 22.83% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Holdings Inc. Common Stock
Report Date
Dec 22, 2025 For Q4 25
Estimate
-$0.57
Actual
-$0.73
Surprise
-25.95%
Outlook Therapeutics, Inc. Common Stock
Report Date
Dec 19, 2025 For Q4 25
Estimate
-$0.25
Actual
-$0.19
Surprise
+26.47%
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
What were Insmed, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Insmed, Inc. reported EPS of -$1.75, missing estimates by -28.09%, and revenue of $142.34M, 20.71% above expectations.
How did the market react to Insmed, Inc.'s Q3 2025 earnings?
The stock price moved up 16.33%, changed from $166.95 before the earnings release to $194.22 the day after.
When is Insmed, Inc. expected to report next?
The next earning report is scheduled for Feb 18, 2026.
What are the forecasts for Insmed, Inc.'s next earnings report?
Based on 19
analysts, Insmed, Inc. is expected to report EPS of -$1.33 and revenue of $174.83M for Q4 2025.